Protagonist Therapeutics, Inc.
NASDAQ:PTGX · NASDAQ Global Market
+$1.72 today
Vol 1.52M · Avg 0.72M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+111.51%
Period High
$112.86
Period Low
$49.70
Latest
$112.86
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
TG Therapeutics, Inc.
NASDAQ:TGTX
$8.05B
Alkermes plc
NASDAQ:ALKS
$7.52B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.49B
Immunovant, Inc.
NASDAQ:IMVT
$7.28B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.57B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.81B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.61B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.60B
What is the latest PTGX filing?
The latest filing shown is 4 dated Jun 11, 2026.
How many recent filings does PTGX have?
Intrinsic Alpha currently shows 20 recent filings for PTGX.
Explore More
Continue the stock analysis
Jump to another research area for this company.